The RIPK3 gene (Receptor-Interacting Serine/Threonine-Protein Kinase 3) encodes a critical kinase that mediates necroptosis, a form of programmed cell death distinct from apoptosis. RIPK3 has emerged as an important player in neurodegenerative diseases, where necrotic cell death contributes to disease progression in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis.
| Attribute |
Value |
| Symbol |
RIPK3 |
| Full Name |
Receptor-Interacting Serine/Threonine-Protein Kinase 3 |
| Chromosomal Location |
14q11.2 |
| NCBI Gene ID |
8767 |
| OMIM ID |
604466 |
| Ensembl ID |
ENSG00000129465 |
| UniProt ID |
Q9Y2K6 |
| Protein Size |
518 amino acids |
| Molecular Weight |
~57 kDa |
RIPK3 contains several functional domains:
- N-terminal Kinase Domain (KD): Serine/threonine kinase activity
- Intermediate Domain (ID): RHIM binding interface
- C-terminal Death Domain (DD): Protein-protein interactions
The RHIM (RIP Homotypic Interaction Motif) is critical for interactions with RIPK1 and other RHIM-containing proteins.
RIPK3 is the central effector of necroptosis:
- Activation: Triggered by TNF family ligands, viral infections, or Toll-like receptor activation
- RIPK1 Recruitment: Forms necrosome complex with RIPK1 via RHIM
- MLKL Phosphorylation: RIPK3 phosphorylates MLKL (Mixed Lineage Kinase domain-like), executing necroptosis
- Membrane Pore Formation: Phosphorylated MLKL translocates to plasma membrane
- Innate Immunity: Defense against viral infections
- Inflammatory Responses: Releases DAMPs (Damage-Associated Molecular Patterns)
- Development: Required for embryonic development in mice
RIPK3 is expressed in most tissues with notable expression in:
In the brain, RIPK3 expression increases in response to injury and disease.
RIPK3-mediated necroptosis contributes to AD progression:
- Neuronal Loss: Necroptosis accounts for progressive neuronal death
- Neuroinflammation: RIPK3 activation triggers inflammatory responses
- Amyloid and Tau Interaction: Aβ and tau pathology activates RIPK3
- Therapeutic Target: RIPK3 inhibitors are being explored
- Dopaminergic Neuron Death: RIPK3 contributes to death of substantia nigra neurons
- Mitochondrial Dysfunction: Links to PINK1/Parkin pathways
- Neuroinflammation: Microglial activation via necroptotic signaling
- Motor Neuron Death: RIPK3 activation in motor neurons
- Astrocyte Involvement: Astrocyte necroptosis releases toxic factors
- Therapeutic Potential: RIPK3 inhibitors show promise in models
- Demyelination: Oligodendrocyte necroptosis
- Neuroinflammation: Immune cell-mediated pathology
| Drug/Compound | Mechanism | Status |
|---------------|-----------||
| Nec-1 (Necrostatin-1) | RIPK1 inhibitor, blocks necroptosis | Preclinical |
| GSK'872 | RIPK3 kinase inhibitor | Research |
| Deguelin | RIPK3 inhibitor | Research |
| Anti-RIPK3 antibodies | Neutralizing antibodies | Preclinical |
RIPK3 interacts with multiple pathways:
- TNF Signaling: Downstream of TNFR1
- TLR Signaling: Activated by TLR3/4
- ZBP1/DAI Pathway: DNA virus sensing
- Caspase-8: Inhibits necroptosis when active
- RIPK3 knockout mice are viable but show altered responses to injury
- Human post-mortem brain tissue shows increased RIPK3 in AD and PD
- Necroptosis inhibitors show neuroprotective effects in animal models